Loading...
XKRX003120
Market cap76mUSD
Jan 09, Last price  
16,400.00KRW
1D
-2.79%
1Q
-0.12%
Jan 2017
-33.33%
Name

Ilsung Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:003120 chart
P/E
—
P/S
1.43
EPS
—
Div Yield, %
26.53%
Shrs. gr., 5y
0.80%
Rev. gr., 5y
4.83%
Revenues
78.05b
+27.44%
78,833,528,00079,870,404,00071,467,214,00068,594,693,00068,191,775,02077,160,760,62062,807,489,69062,828,920,56061,745,116,14067,463,384,16067,043,035,12061,652,595,25048,411,627,88040,600,732,25042,089,835,82061,247,846,53078,053,232,120
Net income
-20.94b
L
17,699,848,00034,163,059,0008,049,787,0006,297,465,00035,083,007,47036,451,736,0807,955,018,2804,034,563,91098,853,930,9303,017,242,0402,628,652,9302,945,528,7406,718,550,3603,220,256,800-1,367,510,420108,669,345,880-20,940,893,247
CFO
-41.47b
L+6.44%
4,171,398,00016,535,708,0001,265,121,00018,644,306,0008,244,202,610-11,318,601,8705,063,947,6204,190,571,1006,041,134,630-31,013,469,62010,158,675,33015,091,217,1604,388,672,7101,557,299,4605,704,073,470-38,966,011,120-41,474,992,530
Dividend
Dec 27, 20231500 KRW/sh

Profile

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
URL
https://www.ilsung-ph.co.kr
IPO date
Jan 14, 1985
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
78,053,232
27.44%
61,247,847
45.52%
Cost of revenue
67,641,831
49,606,210
Unusual Expense (Income)
NOPBT
10,411,401
11,641,637
NOPBT Margin
13.34%
19.01%
Operating Taxes
(404,043)
32,731,670
Tax Rate
281.16%
NOPAT
10,815,443
(21,090,034)
Net income
(20,940,893)
-119.27%
108,669,346
-8,046.51%
Dividends
(29,656,640)
(1,150,326)
Dividend yield
17.93%
0.18%
Proceeds from repurchase of equity
(14,994,854)
(4,228,703)
BB yield
9.07%
0.67%
Debt
Debt current
118,448
92,544
Long-term debt
357,804
456,158
Deferred revenue
900,833
1,135,833
Other long-term liabilities
523,626
Net debt
(286,355,291)
(324,770,880)
Cash flow
Cash from operating activities
(41,474,993)
(38,966,011)
CAPEX
(7,726,712)
(62,495,762)
Cash from investing activities
(26,945,776)
266,825,910
Cash from financing activities
(44,522,944)
(5,736,256)
FCF
12,002,733
113,186,097
Balance
Cash
235,420,194
299,931,184
Long term investments
51,411,349
25,388,398
Excess cash
282,928,881
322,257,190
Stockholders' equity
472,464,063
920,993,870
Invested Capital
101,487,384
95,067,578
ROIC
11.01%
ROCE
2.71%
2.76%
EV
Common stock shares outstanding
6,993
37,388
Price
23,650.00
40.11%
16,880.00
14.36%
Market cap
165,396,015
-73.79%
631,117,458
457.56%
EV
(120,959,276)
306,346,578
EBITDA
13,497,023
14,735,682
EV/EBITDA
20.79
Interest
23,874
12,634
Interest/NOPBT
0.23%
0.11%